Clinical Trial Update: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the fixed ratio combination of insulin glargine/lixisenatide versus insulin glargine in type 2 diabetes; results completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• insulin glargine/lixisenatide fixed-ratio combination (insulin glargine, lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED